⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNGX News
Soligenix, Inc. Common Stock
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Announces Closing of $7.5 Million Public Offering
prnewswire.com
SNGX
Soligenix Announces Pricing of $7.5 Million Public Offering
prnewswire.com
SNGX
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
prnewswire.com
SNGX